These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35527558)

  • 1. Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.
    McCarter SJ; Lesnick TG; Lowe VJ; Rabinstein AA; Przybelski SA; Algeciras-Schimnich A; Ramanan VK; Jack CR; Petersen RC; Knopman DS; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Graff-Radford J
    J Alzheimers Dis; 2022; 87(4):1537-1547. PubMed ID: 35527558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
    Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC
    Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
    Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
    JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
    Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
    Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
    Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
    Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease.
    Guo T; Li A; Sun P; He Z; Cai Y; Lan G; Liu L; Li J; Yang J; Zhu Y; Zhao R; Chen X; Shi D; Liu Z; Wang Q; Xu L; Zhou L; Ran P; Wang X; Sun K; Lu J; Han Y
    Mol Neurodegener; 2024 Jul; 19(1):58. PubMed ID: 39080744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
    Rissman RA; Langford O; Raman R; Donohue MC; Abdel-Latif S; Meyer MR; Wente-Roth T; Kirmess KM; Ngolab J; Winston CN; Jimenez-Maggiora G; Rafii MS; Sachdev P; West T; Yarasheski KE; Braunstein JB; Irizarry M; Johnson KA; Aisen PS; Sperling RA;
    Alzheimers Dement; 2024 Feb; 20(2):1214-1224. PubMed ID: 37932961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting amyloid PET and tau PET stages with plasma biomarkers.
    Jack CR; Wiste HJ; Algeciras-Schimnich A; Figdore DJ; Schwarz CG; Lowe VJ; Ramanan VK; Vemuri P; Mielke MM; Knopman DS; Graff-Radford J; Boeve BF; Kantarci K; Cogswell PM; Senjem ML; Gunter JL; Therneau TM; Petersen RC
    Brain; 2023 May; 146(5):2029-2044. PubMed ID: 36789483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Asken BM; Tanner JA; VandeVrede L; Mantyh WG; Casaletto KB; Staffaroni AM; La Joie R; Iaccarino L; Soleimani-Meigooni D; Rojas JC; Gardner RC; Miller BL; Grinberg LT; Boxer AL; Kramer JH; Rabinovici GD
    Neurology; 2022 Aug; 99(6):e594-e604. PubMed ID: 35577574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
    Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
    JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral Microbleed Patterns and Cortical Amyloid-β: The ARIC-PET Study.
    Okine DN; Knopman DS; Mosley TH; Wong DF; Johansen MC; Walker KA; Jack CR; Kantarci K; Pike JR; Graff-Radford J; Gottesman RF
    Stroke; 2023 Oct; 54(10):2613-2620. PubMed ID: 37638398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
    Huang Y; Li Y; Xie F; Guo Q
    CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
    Mattsson-Carlgren N; Collij LE; Stomrud E; Pichet Binette A; Ossenkoppele R; Smith R; Karlsson L; Lantero-Rodriguez J; Snellman A; Strandberg O; Palmqvist S; Ashton NJ; Blennow K; Janelidze S; Hansson O
    JAMA Neurol; 2024 Jan; 81(1):69-78. PubMed ID: 38048096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
    Meyer PF; Ashton NJ; Karikari TK; Strikwerda-Brown C; Köbe T; Gonneaud J; Pichet Binette A; Ozlen H; Yakoub Y; Simrén J; Pannee J; Lantero-Rodriguez J; Labonté A; Baker SL; Schöll M; Vanmechelen E; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
    Ann Neurol; 2022 Apr; 91(4):548-560. PubMed ID: 35084051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
    Brickman AM; Manly JJ; Honig LS; Sanchez D; Reyes-Dumeyer D; Lantigua RA; Lao PJ; Stern Y; Vonsattel JP; Teich AF; Airey DC; Proctor NK; Dage JL; Mayeux R
    Alzheimers Dement; 2021 Aug; 17(8):1353-1364. PubMed ID: 33580742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
    Bali D; Hansson O; Janelidze S
    Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.